Research & Innovation

Innovation
fueled by Passion

While supporting existing assets and developing new indications to address unmet needs, our Research & Development Department is focused on three main therapeutic areas: gastroenterology, vascular disease & neuroscience disorders.
Our new strategic plan deals with next decades challenges in healthcare, leveraging opportunities in precision medicine, maximizing existing competencies in microbiome, acquiring new assets in late stage development.
We are partnering with other organizations to exploit new opportunities through big data, new technologies, and patient engagement projects.

Our main R&D therapeutic areas
Pipeline
Life Cycle

Gastroenterology

Pipeline

5 projects
(3 in clinical development)

Life Cycle
Normix, Tixteller, Xifaxan (rifaximin) Fully developed by Alfasigma Indicated for Hepatic Encephalopaty, Traveler’s diarrhea, IBS

Vascular

Pipeline

1 project

Life Cycle

Vessel (Sulodexide)

Fully developed by Alfasigma

Indicated for Venous disorders (CVI, rDVT), Arterial disorders (PAOD)

Neuroscience

Pipeline

New projects under assessment

Life Cycle

Deplin (L-Methylfolate)

Indicated as Medical
Food for co-treatment
in Depressive
Disorders

Microbiome as main innovation R&D engines

Rifaximin

is one of the most effective microbiome modifier on the market

Irritable
Bowel Disease

Hepatic
Encephalopathy

Novel agents

Under exploration

Read More

Mutual growth, transparency and patient centricity are the values that guide our dialogue with the medical community.
Reporting an adverse event is important in order to safeguard the patients who are taking it and ensure a favourable benefit-risk balance for the population.

Csr

During COVID-19 emergency, we strived to solidify and maintain our relationships with stakeholders by supporting them through numerous initiatives across the world.